🇺🇸 FDA
Patent

US 8143226

Tyrosine kinase receptor antagonists and methods of treatment for breast cancer

granted A61KA61K31/404A61K31/70

Quick answer

US patent 8143226 (Tyrosine kinase receptor antagonists and methods of treatment for breast cancer) held by The Regents of the University of California expires Mon Mar 22 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Mar 27 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 22 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K31/404, A61K31/70, A61P, A61P35/00